Roche is 'e­val­u­at­ing po­ten­tial op­tion­s' for IPF drug Es­bri­et as gener­ics gain trac­tion

Roche is look­ing to of­fload its id­io­path­ic pul­monary fi­bro­sis drug Es­bri­et as more pa­tients with the fa­tal lung dis­ease opt for gener­ic ver­sions and Big Phar­mas con­tin­ue to shed non-core as­sets.

“As part of the nor­mal process to re­view our port­fo­lio of es­tab­lished prod­ucts, we are cur­rent­ly eval­u­at­ing po­ten­tial op­tions for Es­bri­et. This process will take sev­er­al months un­til a fi­nal de­ci­sion is tak­en,” a Roche spokesper­son con­firmed to End­points News via an emailed state­ment on Tues­day morn­ing.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.